Alprolix (Coagulation Factor Ix Drug Interactions: 40 Major
Alprolix (Coagulation Factor Ix (Recombinant), Fc Fusion Protein) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Alprolix. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Eftrenonacog alfa.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eftrenonacog alfa.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Eftrenonacog alfa.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Eftrenonacog alfa.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Eftrenonacog alfa.
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eftrenonacog alfa.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Eftrenonacog alfa.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Eftrenonacog alfa.
Level 2 evidence
Enter your NPI to unlock 24 major interactions for Alprolix
Alprolix (Coagulation Factor Ix (Recombinant), Fc Fusion Protein) has 203 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Alprolix (Coagulation Factor Ix (Recombinant), Fc Fusion Protein) has 40 major, 1 moderate, and 162 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Alprolix. Always confirm against the full prescribing information.